期刊
ONCOTARGET
卷 5, 期 12, 页码 4438-4451出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.2034
关键词
Rg(3); autophagy; HCC; doxorubicin; cell death
资金
- National Research Foundation of Korea (NRF) - Korea government (MEST) [2011-0030043, 2012R1A1A2008713, 2012R1A2A2A01045602]
- National Research Foundation of Korea [2012R1A1A2008713, 2012R1A2A2A01045602] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. High mortality from HCC is mainly due to widespread prevalence and the lack of effective treatment, since systemic chemotherapy is ineffective, while the targeted agent Sorafenib extends median survival only briefly. The steroidal saponin 20(S)-ginsenoside Rg(3) from Panax ginseng C. A. Meyer is proposed to chemosensitize to various therapeutic drugs through an unknown mechanism. Since autophagy often serves as cell survival mechanism in cancer cells exposed to chemotherapeutic agents, we examined the ability of Rg(3) to inhibit autophagy and chemosensitize HCC cell lines to doxorubicin in vitro. We show that Rg(3) inhibits late stage autophagy, possibly through changes in gene expression. Doxorubicin-induced autophagy plays a protective role in HCC cells, and therefore Rg(3) treatment synergizes with doxorubicin to kill HCC cell lines, but the combination is relatively nontoxic in normal liver cells. In addition, Rg(3) was well-tolerated in mice and synergized with doxorubicin to inhibit tumor growth in HCC xenografts in vivo. Since novel in vivo inhibitors of autophagy are desirable for clinical use, we propose that Rg(3) is such a compound, and that combination therapy with classical chemotherapeutic drugs may represent an effective therapeutic strategy for HCC treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据